Completion of dosing for 5,041 subjects in the Phase 2b NAVIGATE clinical trial, indicating significant progress in the development of CD388 for influenza prevention. Publication of preclinical data ...
The company expects to complete recruitment for the Phase III LUCIDITY trial of Avexitide by the end of 2025, with top line data anticipated in the first half of 2026. Top line data from the Phase IIb ...
Celcuity (CELC) recently released positive results from its phase 3 VIKTORIA-1 trial, which used its drug gedatolisib in combination with other therapies to treat patients with PIK3CA wildtype ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results